Canaccord lowered the firm’s price target on Adicet Bio (ACET) to $18 from $128 and keeps a Buy rating on the shares. The firm adjusted its price target to reflect a one-for 16 reverse stock split that took effect on December 30, 2025, to maintain listing requirements on the NASDAQ. This reverse split results in a total of approximately 9.6 million shares of common stock outstanding.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ACET: